期刊
CURRENT GENOMICS
卷 18, 期 3, 页码 244-254出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389202918666170105094459
关键词
Papillary microcarcinoma of the thyroid; mPTC; BRAF; RAS; TERT; RET/PTC; Genetics; Prognosis
资金
- CNPq (National Counsel of Technological and Scientific Development, Brazil) [99999.006726/2015-01]
- FCT
- Portuguese Foundation for Science and Technology
- Programa Operacional Regional do Norte under Quadro de Referencia Estrategico Nacional (QREN) [2 - O Novo Norte]
- Fundo Europeu de Desenvolvimento Regional (FEDER)
- FEDER funds through the Operational Programme for Competitiveness Factors - COMPETE
- National Funds through FCT [C/SAU/LA0003/2013]
- project Advancing cancer research: from basic knowledgment to application
- Norte 2020-Programa Operacional Regional do Norte
- [NORTE-01-0145-FEDER-000029]
Papillary microcarcinoma of the thyroid (mPTC) is defined by the WHO as a papillary thyroid cancer measuring 10mm or less in diameter and it is nowadays a topic of intense debate among the members of the medical community due to its apparent epidemic rise. Although these tumors follow almost always an indolent clinical course and carry an excellent prognosis, it is known that a small subset may display a potentially aggressive behavior. Nevertheless, we still lack an accurate way of predicting those which will cause significant disease. In an attempt to address this problem, a number of clinico-pathologic features have been studied as poor prognostic markers in mPTC, and their association with known genetic alterations in thyroid cancer has been evaluated. Herein we review the present knowledge concerning mPTC's genetic profile, namely the prevalence of BRAF (V600E), RAS and TERT promoter mutations and RET/PTC and PAX8-PPARG rearrangements and report the results of the evaluation in the putative prognostic value of these genetic alterations in mPTC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据